Matt Campbell MD, MS
@DocMattCampbell
Followers
719
Following
2K
Media
86
Statuses
520
I am a genitorurinary medical oncologist at UT MD Anderson. I specialize in kidney, urothelial, adrenal and testicular cancer. all opinions are mine.
Houston, TX
Joined January 2024
An honor to take part in the DAVA GU Summit in Bermuda. Great start to the meeting. Proud of @CYJiangMD who presented her work on targeting TGF-B signaling in MTAP loss bladder cancer under mentorship of JJ Gao and @OAlhalabiMD sponsored by @ConquerCancerFd
2
11
27
Dena Battle @RCCadvocate @kcCURE with poignant discussion of perceptions of cure in #kidneycancer. Thereβs a social contract and hope loaded in this word CURE β should we consider remission or other verbiage? @KidneyCancer #IKCSNA25
0
12
27
The #kidneycancer godfather #NizarTannir receives the inaugural mentorship excellence award @KidneyCancer #IKCSNA25 - sharing the award w his mentees and reminding us to pass it forward, give the spotlight, #unstoppabletogether
0
11
33
So happy to take part in #IKCSNA25, great Think Tank chaired by @PavlosMsaouel and @MVossMD focused on optimizing studies for patients with rare subtypes. Very proud today for our work on RCC bone mets modeling to be shown by @dr4gut1n from his work in the BoneMetLab @ED_PhD_
0
10
30
π‘Just released Practice changing study in NEJMπ Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. PFS DV vs chemo (median, 13.1 vs. 6.5 months; Overall survival DV vs Chemo (31.5 vs. 16.9 months;) objective response was DV 76.1% (95% CI, 70.3
0
46
95
An insightful story about AVPC by @aaparicioMD: how to interpret the molecular alterations and how weβve been treating them @MDAndersonNews #ESMO25
0
15
39
Presidential EVP from KN905 in MIBC at #ESMO25 with incredibly strong data. PathCR of 57%! EFS and OS positive, a game changing study. ??? continuation of treatment with EV in those with pCR? Is cisplatin candidacy still relevant for MIBC? Ideal bladder sparing approach next?
1
12
32
Congratulations to @OncHahn, @JadChahoud and the entire team on completing this randomized investigator-initiated multicenter trial. Many thought it was impossible for such a comparison to be completed but you turned it into reality. @neerajaiims @PGrivasMDPhD @montypal
Excited to see LenCabo published concomitant in @Annals_Oncology Plan to post a full tweetorial summarizing our results later @PavlosMsaouel
0
3
22
Our poster assessing prognostic scores in 1L EVP pts. Belmont score: liver mets, ECOG >0, and Hgb<10 was best for predicting OS/PFS . Thanks to UNITE @koshkin85 for this opportunity and incredible mentorship by @DocMattCampbell and @OAlhalabiMD
1
10
25
Excited to see LenCabo published concomitant in @Annals_Oncology Plan to post a full tweetorial summarizing our results later @PavlosMsaouel
π’ #ESMO25 concomitant paper: results from the LenCabo phase II trial of lenvatinib + everolimus vs cabozantinib post PD-1 ICI in #mccRCC @OncHahn
https://t.co/4EmwlwVhqE
1
20
57
Very proud of @CYJiangMD for her great poster at #ESMO25 with prognostic scores for EVP treated patients from UNITE. Bellmunt criteria was the best to differentiate PFS/OS. Good for strata on front line mUC studies comparing to EVP. Great teamwork across centers. @OAlhalabiMD
1
8
35
Congrats to Prof Camilo Jimenez @MDAndersonNews for presenting Ph2 belzutifan in advanced pheo/para with DCR of 80% median PFS nearly 2 years now published in @NEJM first targeted therapy FDA approved in this rare cancer type #ESMO25
0
2
7
First trial of PD1/VEGF bispecific in #kidneycancer just activated today and is @NazliDizmanβs trial design project during her @MDAndersonNews heme/onc fellowship π€ π https://t.co/F2ryVQ8zyV
@brian_rini @montypal @OncHahn @OAlhalabiMD @DocMattCampbell @ChadTangMD @SGoswamiMDPhD
In our latest podcast, John Heymach from @MDAndersonNews reviews exciting PD1/VEGF bispecific data from the lung cancer. We review the data and discuss applications to GU malignancies. https://t.co/c0w1Svk3Ja
2
12
60
Tremendously enjoyed working with @Shounak_Gupta et al on this contemporary update of #RenalMedullaryCarcinoma pathology, pathophysiology, differential diagnosis & management. #kidneycancer #rarecancers #endRMC
Here is an update on medullary RCC. Thank you @PavlosMsaouel for your tremendous contribution to this article and thanks to @MichelleDunno17 for the invitation Open access at: https://t.co/lZ63zBeHNB
0
10
45
Surreal to be completing training in oncology, 14 years after beginning the journey as a freshman in college diagnosed with testicular cancer. I owe so much to my doctors, Dr. Ahmed and Dr. Einhorn, who showed me what it meant to treat patients (and people) with compassion
7
8
139
πLatest treatment & research updates on #RenalMedullaryCarcinoma. #endRMC #RareCancers #kidneycancer
RMC is one of the most aggressive and rare forms of #KidneyCancer. In our latest video, @PavlosMsaouel shares updates on how specialized treatments are improving outcomes for RMC patients. Explore the full Rare Subtypes playlist here: https://t.co/oEjQkQpdQ6
#AcceleratingCures
0
9
43
White Coat Ceremony for my upcoming Internal Medicine Residency at Baylor College of Medicine @BCM_InternalMed - so grateful and blessed! π
6
6
98
We have a couple of years before she gets to making her own videos advocating for #RCC π§‘. Thanks for all you do @KidneyCancer ππ»ππ»
1
1
12